Axsome Therapeutics, Inc. (AXSM) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New York City, NY, United States. The current CEO is Herriot Tabuteau.
AXSM has IPO date of 2015-11-19, 712 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $9.42B.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders. The company's lead candidate, AXS-05, is being evaluated for major depressive disorder, treatment-resistant depression, Alzheimer's disease agitation, and smoking cessation across Phase II and Phase III clinical trials. Its pipeline also includes AXS-07 for acute migraine treatment, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, all in late-stage development. Founded in 2012 and headquartered in New York, Axsome collaborates with leading institutions including Duke University to advance its clinical programs.
